Evident Corporation closed its acquisition of CrestOptics S.p.A. on October 5, 2026, bringing the Rome-based optical systems manufacturer into its microscopy and imaging division. Terms remain undisclosed. The deal adds European manufacturing capacity and advanced spinning-disk confocal technology to Evident's portfolio, which already serves clinical diagnostics, life sciences research, and industrial inspection markets.
CrestOptics develops and manufactures high-speed confocal imaging modules used in live-cell microscopy and advanced fluorescence applications. The company's X-Light spinning-disk systems integrate into third-party microscope platforms, allowing researchers to capture high-resolution cellular dynamics without photodamage. Revenue figures for CrestOptics have not been disclosed, but the company supplies modules to university research labs, pharma R&D groups, and contract research organizations across Europe and North America. Evident, formerly the imaging division of Olympus Corporation before its $3.1 billion sale to Bain Capital in 2019, manufactures endoscopes, microscopes, and industrial videoscopes from facilities in Japan, Germany, and the United States.
The acquisition accelerates Evident's vertical integration in precision optics at a moment when live-cell imaging demand is rising. Pharma groups pursuing cell and gene therapies need real-time visualization of transfection efficiency, organoid development, and immune-cell interactions. Academic labs funded by recent NIH expansions are upgrading to multi-modal imaging systems. CrestOptics' spinning-disk modules slot into these workflows as plug-and-play upgrades, and Evident now controls both the microscope base and the advanced imaging layer. That end-to-end ownership shortens product cycles, tightens quality control, and opens bundling opportunities for integrated systems priced above $200,000 per unit. The Rome facility also gives Evident a Western European production footprint, reducing tariff exposure and shortening delivery times to EU research institutes. Worth noting: the deal follows Evident's $115 million acquisition of NDS Surgical Imaging in 2023, signaling a sustained buy-and-build strategy in adjacent imaging verticals.
Operators should track three follow-on events. First, watch for product announcements integrating CrestOptics modules with Evident's IXplore microscope platform, likely within six to nine months. Second, monitor whether Evident consolidates CrestOptics manufacturing into its Germany or U.S. facilities, or retains Rome as a standalone R&D hub. Third, observe whether competing microscopy suppliers—Nikon, Zeiss, Leica—accelerate their own M&A to match Evident's vertical scope. The sector has fragmented component suppliers; this deal suggests the tier-one players prefer to own critical optics rather than license them.
Evident now holds both the microscope chassis and the precision modules that determine image quality. The competition notices.